Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Horizon scan: CLL and CAR-T

Constantine Tam • 13 May 2020
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors CAR-T Ibrutinib

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, talks on CAR T-cell therapy in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Constantine Tam

1:13
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam • 11 Dec 2023
2:06
The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies
Constantine Tam • 11 Dec 2023
1:52
SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL
Constantine Tam • 11 Dec 2023
2:36
Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL
Constantine Tam • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals